Trials / Active Not Recruiting
Active Not RecruitingNCT07028749
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
Phase 2b Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of MAR001 in Patients With Elevated Triglycerides and Remnant Cholesterol (TYDAL-TIMI 78)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 216 (estimated)
- Sponsor
- Marea Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of the TG and RC in adults with elevated TG and RC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MAR001 | Subcutaneous Injection |
| DRUG | Placebo | Subcutaneous injection |
Timeline
- Start date
- 2025-06-30
- Primary completion
- 2026-07-01
- Completion
- 2026-12-01
- First posted
- 2025-06-19
- Last updated
- 2026-01-26
Locations
54 sites across 4 countries: United States, Australia, Canada, New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07028749. Inclusion in this directory is not an endorsement.